NCT06838286 - Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 Diabetes | Biotech Hunter

Enrollment

10,000

Participants

Timeline

Start Date

March 16, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2029

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

SGLT2 inhibitor

SGLT2 inhibitor class of drugs

DRUG

Thiazolidinedione

Thiazolidinedione class of drugs

DRUG

DPP-4 inhibitor

DPP4 inhibitor class of drugs

Trial Locations (1)

RECRUITING

Seoul National University Bundang Hospital, Seongnam-si